This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
Chimeric antigen receptor T-cell medicines could have more risks than previously known. Novartis' drug Kymriah is going to be under the most scrutiny for now.
Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.
Bristol Myers Squibb Co. BMY, -0.70% announced an additional $3 billion share buyback program on Thursday, boosting the full authorization to about $5 billion. The stock rose 1% premarket but is down

Bristol Myers Squibb raises dividend by 5.3%

05:14pm, Wednesday, 06'th Dec 2023
Bristol Myers Squibb Co. BMY, -0.70% said late Wednesday that its board has declared a quarterly dividend of 60 cents a share, a 5.3% increase over last year's dividend of 57 cents a share. The divide
Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.

3 Dirt-Cheap Stocks That Could Skyrocket

11:23am, Tuesday, 05'th Dec 2023
Shares of China's e-commerce giant Alibaba continue to lose ground despite the company's clear top- and bottom-line growth. Pharmaceutical outfit Bristol-Myers Squibb has had a tough year.
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.
Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY).  The pact is focused on the discovery, dev
Bristol-Myers Squibb Company is down 40%, while the market is up 20%. The reason is the collapse in its growth outlook created by patent cliffs. Despite some amazing growth in new drugs, Bristol's thr
Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent
Although the stock market whipsawed investors over the past few years, it showed its resilience by bouncing sharply higher after the pandemic collapse. As it has for more than a century, every double-
When bad news happens to good companies, it just might be a signal to consider buying shares. Johnson Controls has a solid business, but its stock is down thanks to less-than-ideal guidance.
Investors should consider selling stocks with negative catalysts and at risk of further decline. Taxable account holders may realize losses to offset this year's capital gains. Avoid Companies with hi
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE